Related Experiment Video
Updated: Jun 12, 2026
13:14
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Generating recombinant antibodies to the complete human proteome.
Stefan Dübel1, Oda Stoevesandt, Michael J Taussig
1Technische Universität Braunschweig, Institute of Biochemistry and Biotechnology, D-38106 Braunschweig, Germany. s.duebel@tu-bs.de
Trends in Biotechnology
|June 12, 2010
Summary
In vitro antibody generation methods offer advantages over animal-based techniques for creating research reagents. These advanced technologies enable the development of comprehensive antibody resources for human proteome research.
Area of Science:
- Biotechnology
- Immunology
- Proteomics
Background:
- In vitro antibody generation technologies have been available for 20 years.
- Phage display is a key technology for in vitro antibody production.
- Current advancements allow for comprehensive antibody generation for the human proteome.
Purpose of the Study:
- To summarize opportunities for generating antibodies for proteome research using in vitro technologies.
- To highlight the advantages of in vitro antibody generation over traditional animal-based methods.
Main Methods:
- In vitro antibody selection using phage display.
- Optimization of selection conditions to control antigen conformation, affinity, and cross-reactivity.
- Utilizing bacterial production for cost-effective, large-scale antibody generation.
Main Results:
- In vitro antibody generation is now advanced enough for comprehensive proteome-wide antibody resources.
- In vitro methods offer control over antibody properties like antigen recognition and affinity.
- Bacterial production and DNA sequence availability provide logistical and modification benefits.
Conclusions:
- In vitro antibody generation technologies present significant opportunities for proteome research.
- These methods offer superior control, cost-effectiveness, and flexibility compared to animal-based approaches.
- The development of renewable antibody resources is feasible for all human protein-coding genes.
